Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Phase II Umbrella Study Directed by Next Generation Sequencing
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 400
- Registration Number
- NCT03574402
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT03566576
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 442
- Registration Number
- NCT03564691
- Locations
- 🇨🇦
Princess Margaret Cancer Centre ( Site 0033), Toronto, Ontario, Canada
🇺🇸Seattle Cancer Care Alliance ( Site 0010), Seattle, Washington, United States
🇺🇸University of California at San Francisco ( Site 0004), San Francisco, California, United States
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT03559049
- Locations
- 🇺🇸
The University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 401
- Registration Number
- NCT03530397
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
- Conditions
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 492
- Registration Number
- NCT03515837
- Locations
- 🇨🇳
Tangdu Hospital ( Site 0708), XI An, Shanxi, China
🇨🇳Southwest Hospital, The Third Military Medical University ( Site 0725), Chongqing, Chongqing, China
🇨🇳Henan Cancer Hospital ( Site 0711), Zhengzhou, Henan, China
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- Drug: DurvalumabDrug: Cisplatin (dose level 4)Drug: Etoposide (dose level 1)Drug: Carboplatin (dose level 1)Drug: Carboplatin (dose level 2)Drug: Cisplatin (dose level 3)Drug: TremelimumabRadiation: External beam radiation (dose level 1)Drug: PemetrexedDrug: PaclitaxelDrug: Cisplatin (dose level 1)Radiation: External beam radiation (dose level 2)Drug: Etoposide (dose level 2)Drug: Cisplatin (dose level 2)Radiation: External beam radiation (standard)Radiation: External beam radiation (hyperfractionated)
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT03509012
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 34
- Registration Number
- NCT03507244
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin
- Conditions
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Queen Mary University of London
- Registration Number
- NCT03498222
Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 45
- Registration Number
- NCT03489616
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
🇨🇳SHANDONG Cancer Hospital, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.